Shares of the pharma major Biocon surged over 2% in the early session of December 29 after the company launched Tacrolimus capsules in the US. It is used after allogeneic organ transplant to lower the risk of organ rejection, and also as a topical medication in the treatment of T-cell-mediated diseases such as eczema and psoriasis.At 09:32 AM IST, Biocon was trading at Rs 470 up by Rs 4.90, or 1.05 percent on the BSE. The stock touched its 52-week high Rs 487.70 on December 23 and 52-week low Rs 235.80 on 19 March 2020.
Shares of Biocon add 2% after launching Tacrolimus capsules in the US
